Blood Research Institute, Versiti Wisconsin, Milwaukee, WI, USA.
Oncology Discovery, AbbVie Inc., North Chicago, IL, USA.
Nat Commun. 2019 Jan 14;10(1):190. doi: 10.1038/s41467-018-08122-9.
A number of different B cell subsets have been shown to exhibit regulatory activity using a variety of mechanisms to attenuate inflammatory diseases. Here we show, using anti-CD20-mediated partial B cell depletion in mice, that a population of mature B cells distinguishable by IgD expression maintains tolerance by, at least in part, promoting CD4Foxp3 regulatory T cell homeostatic expansion via glucocorticoid-induced tumor necrosis factor receptor ligand, or GITRL. Cell surface phenotyping, transcriptome analysis and developmental study data show that B cells expressing IgD at a low level (BD) are a novel population of mature B cells that emerge in the spleen from the transitional-2 stage paralleling the differentiation of follicular B cells. The cell surface phenotype and regulatory function of BD are highly suggestive that they are a new B cell subset. Human splenic and peripheral blood IgD B cells also exhibit BD regulatory activity, rendering them of therapeutic interest.
已经有研究表明,多种不同的 B 细胞亚群可以通过多种机制发挥调节作用,从而减轻炎症性疾病。在这里,我们通过抗 CD20 介导的部分 B 细胞耗竭实验,在小鼠中证明了一类成熟 B 细胞(通过 IgD 表达可区分)通过糖皮质激素诱导的肿瘤坏死因子受体配体(GITRL)至少部分促进 CD4Foxp3 调节性 T 细胞稳态扩增,从而维持耐受。细胞表面表型分析、转录组分析和发育研究数据表明,表达低水平 IgD 的 B 细胞(BD)是一类新型成熟 B 细胞,在过渡 2 期从脾脏中出现,与滤泡 B 细胞的分化平行。BD 的细胞表面表型和调节功能强烈提示它们是一种新的 B 细胞亚群。人类脾脏和外周血 IgD B 细胞也表现出 BD 的调节活性,这使得它们具有治疗意义。